The FDA will take action on its application in late 2008. Sumatriptan DosePro (formerly known as Intraject sumatriptan) utilizes Zogenix’s proprietary DosePro needle-free drug delivery system to subcutaneously administer sumatriptan.
Roger Hawley, CEO of Zogenix, said: “We are very pleased to have our first new drug application (NDA) accepted for filing by the FDA. In just 18 months, we have progressed from a start-up stage company to one now with our first product under review by the FDA for approval.”